Teriparatide

Teriparatide

Clinical data
Pregnancy category	C
Routes of administration	SubQ
ATC code	H05AA02 (WHO)
Pharmacokinetic data
Bioavailability	95%
Metabolism	Hepatic (nonspecific proteolysis)
Elimination half-life	SubQ: 1 hour
Excretion	Renal (metabolites)
Identifiers
PubChem CID	16133850
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C181H291N55O51S2
Molar mass	4117.72 g/mol

WikiDoc Resources for Teriparatide
Articles
Most recent articles on Teriparatide Most cited articles on Teriparatide Review articles on Teriparatide Articles on Teriparatide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Teriparatide Images of Teriparatide Photos of Teriparatide Podcasts & MP3s on Teriparatide Videos on Teriparatide
Evidence Based Medicine
Cochrane Collaboration on Teriparatide Bandolier on Teriparatide TRIP on Teriparatide
Clinical Trials
Ongoing Trials on Teriparatide at Clinical Trials.gov Trial results on Teriparatide Clinical Trials on Teriparatide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Teriparatide NICE Guidance on Teriparatide NHS PRODIGY Guidance FDA on Teriparatide CDC on Teriparatide
Books
Books on Teriparatide
News
Teriparatide in the news Be alerted to news on Teriparatide News trends on Teriparatide
Commentary
Blogs on Teriparatide
Definitions
Definitions of Teriparatide
Patient Resources / Community
Patient resources on Teriparatide Discussion groups on Teriparatide Patient Handouts on Teriparatide Directions to Hospitals Treating Teriparatide Risk calculators and risk factors for Teriparatide
Healthcare Provider Resources
Symptoms of Teriparatide Causes & Risk Factors for Teriparatide Diagnostic studies for Teriparatide Treatment of Teriparatide
Continuing Medical Education (CME)
CME Programs on Teriparatide
International
Teriparatide en Espanol Teriparatide en Francais
Business
Teriparatide in the Marketplace Patents on Teriparatide
Experimental / Informatics
List of terms related to Teriparatide

Teriparatide (Forteo®) is a recombinant form of parathyroid hormone, used in the treatment of advanced osteoporosis. It is manufactured and marketed by Eli Lilly and Company.

Administration

Teriparatide is administered by injection once a day in the thigh or abdomen. The recommended dose is 20 μg per day.

Uses

Teriparatide has recently been given to patients in an ongoing clinical trial to evaluate its effectiveness in treating the symptoms of osteogenesis imperfecta.

Teriparatide should not be prescribed for patients who are at increased risks for osteosarcoma. This includes those with Paget's Disease of bone or unexplained elevations of serum alkaline phosphate, open epiphysis, or prior radiation therapy involving the skeleton.

Mechanism of action

Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.

Teriparatide is the first FDA approved agent for the treatment of osteoporosis that stimulates new bone formation.

FDA approval

Teriparatide was approved by the Food and Drug Administration (FDA) on 26 November, 2002, for the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. The drug is also approved to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.

External links

• Teriparatide at National Institutes for Health.

Template:WikiDoc Sources